Targeted Metallo-Drugs

This MILS-24 volume provides a comprehensive overview of recent advances in the development of new metal-based drugs as anti-cancer, anti-microbial and anti-viral agents which have been designed specifically to overcome toxic side effects and/or resistance issues associated with current drug treatments.

---

Volume 24, entitled Targeted Metallo-Drugs: Design, Development, and Modes of Action, of the series Metal Ions in Life Sciences (MILS), fosters inter-disciplinary research in the vibrant field of Biological Inorganic Chemistry. Inspired by the clinical success of cisplatin as a leading anticancer drug but mindful of the shortcomings associated with its use including dose-limiting toxic side effects and acquired or intrinsic drug resistance, scientists across the globe have been endeavoring to identify new metallo-drugs for therapeutic exploitation. This has led to innovative metallo-drug candidates that (i) enhance cancer cell selectivity, thus reducing toxic side effects, and/or (ii) possess new modes of action to improve efficacy and also target resistance pathways. This and more are captured in MILS- 24 which consists of 12 comprehensive, well-illustrated, and up to date chapters with over 1600 citations, 100 figures, and 10 tables with key contributions from 32 international experts from Europe, Asia, and North and South America. MILS- 24 not only keeps the scientific community abreast of latest developments, it also serves as an invaluable resource to stimulate further research on targeted metallo-drug design and development.



It covers anticancer, antimicrobial, antiviral, and other agents, such as those targeting tropical diseases and cyanide poisoning and radiometals in molecular imaging and therapy
It highlights recent metallo-drug developments targeting COVID-19
It features advanced spectroscopic methods and metallomics as important tools to elucidate the modes of actions of metallo-drugs